Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 9/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | STK17B | O94768 | 1/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.35 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31430396 | 1.00 | MAPKAPK2 (0.41) | MAPKAPK2MAP4K4MAPK14SYKHDAC1 | |
| SCHEMBL24364156 | 0.83 | MAPKAPK2 (0.40) | MAPKAPK2MAP4K4SYKATRPRMT1 | |
| SCHEMBL30469570 | 0.83 | MAPKAPK2 (0.40) | MAPKAPK2MAP4K4SYKATRPRMT1 | |
| SCHEMBL6517445 | 0.82 | MAPKAPK2 (0.40) | MAPKAPK2MAP4K4SYKATRPRMT1 | |
| SCHEMBL24364781 | 0.82 | MAPKAPK2 (0.39) | MAPKAPK2MAP4K4MAPK14SYKCYP17A1 | |
| SCHEMBL24364864 | 0.81 | MAP4K4 (0.42) | MAPKAPK2MAP4K4SYKATRPRMT1 | |
| SCHEMBL24367667 | 0.81 | ALDH1A1 (0.40) | MAPKAPK2MAP4K4SYKATRPRMT1 | |
| SCHEMBL29477633 | 0.81 | ALDH1A1 (0.40) | MAPKAPK2MAP4K4SYKATRPRMT1 | |
| SCHEMBL32689297 | 0.80 | MAPKAPK2 (0.35) | MAPKAPK2MAP4K4MAPK14SYKHDAC1 | |
| SCHEMBL24366932 | 0.80 | LMNA (0.40) | MAPKAPK2MAP4K4SYKATRPRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | MAPKAPK2 4853/4885MAP4K4 4660/4885MAPK14 4784/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | MAPKAPK2 4853/4885MAP4K4 4660/4885MAPK14 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.